Fig. 1
From: Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer
Therapeutic effect of pyrotinib and chrysin on HER2-positive breast cancer in vitro and in vivo. a, b Western blot (a) and RT-qPCR (b) analysis of HER2 expression levels in various breast cancer cell lines of MCF-7, SK-BR-3, BT-474, MDA-MB-231 (n = 3). c Cell viability of SK-BR-3 cells received various treatments (n = 3). d Detection of cell cycle arrest of SK-BR-3 cells after various treatments (n = 3). e Schematic diagram of the established protocol of the animal models. Photograph of resected tumor tissues of mice in different treatment groups during the whole testing period (n = 6). f, g Tumor volume (f) and tumor weight (g) variations of mice in four treatment groups over 45 days (n = 6). h H&E, Ki67, and Tunnel immunohistochemical staining of tumor sections of mice in various treatment groups. i body weight changes in different treatment groups during the whole testing period. All bar values are represented as mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001. NS, not significant
